Bulletin of Experimental Biology and Medicine

, Volume 156, Issue 1, pp 44–48 | Cite as

Aptamer RA36 Inhibits of Human, Rabbit, and Rat Plasma Coagulation Activated with Thrombin or Snake Venom Coagulases

  • E. Yu. Savchik
  • T. B. Kalinina
  • N. N. Drozd
  • V. A. Makarov
  • E. G. Zav’yalova
  • E. N. Lapsheva
  • N. N. Mudrik
  • A. V. Babij
  • G. V. Pavlova
  • A. V. Golovin
  • A. M. Kopylov
Article

RA36 DNA aptamer is a direct anticoagulant prolonging clotting time of human, rabbit, and rat plasma in the thrombin time test. Anticoagulant activity of RA36 is lower than that of recombinant hirudin. During inhibition of human plasma clotting activated with echitox (coagulase from Echis multisquamatus venom), the aptamer presumably binds to meisothrombin exosite I. The sensitivity of human plasma to the aptamer 5-fold surpasses that of rat plasma. Analysis of RA36 binding to coagulase of Agkistrodon halys venom (ancistron) is required for proving the effect of aptamer on polymerization of human fibrinogen.

Key Words

aptamer plasma coagulation thrombin snake venom coagulases 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Z. Barkagan and A. Momot, Diagnosis and Controlled Therapy for Hemostasis Disorders [in Russian], Moscow (2001).Google Scholar
  2. 2.
    T. Platonova, O. Sushko, N. Lukinova, et al., Fiziol. Zh., 40, Nos. 3–4, 63–70 (1994).PubMedGoogle Scholar
  3. 3.
    E. Di Cera, Mol. Aspects Med., 29, No. 4, 203–254 (2008).PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    M. F. Doyle and K. G. Mann, J. Biol. Chem., 265, No. 18, 10,693–10,701 (1990).Google Scholar
  5. 5.
    E. J. Favaloro, G. Lippi, and J. Koutts, Pathology, 43, No. 7, 682–692 (2011).PubMedCrossRefGoogle Scholar
  6. 6.
    L. M. Haynes, Y. C. Dubief, T. Orfeo, and K. G. Mann, Biophys. J., 100, No. 3, 765–773 (2011).PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    C. A. Holland, A. T. Henry, H. C. Whinna, and F. C. Church, FEBS Lett., 484, No. 2, 87–91 (2000).PubMedCrossRefGoogle Scholar
  8. 8.
    G. Mayer, F. Rohrbach, B. Pötzsch, and J. Muller, Haemostaseologie, 31, No. 4, 258–263 (2011).CrossRefGoogle Scholar
  9. 9.
    J. Müller, D. Freitag, G. Mayer, and B. Pötzsch, J. Thromb. Haemost., 6, No. 12, 2105–2112 (2008).PubMedCrossRefGoogle Scholar
  10. 10.
    R. N. Pike, A. M. Buckle, B. F. le Bonniec, and F. C. Church, FEBS J., 272, No. 19, 4842–4851 (2005).PubMedCrossRefGoogle Scholar
  11. 11.
    A. S. Soon, S. E. Stabenfeld, W. F. Brown, and T. H. Barker, Biomaterials, 31, No. 7, 1944–1954 (2010).PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    T. E. Warkentine, Best Prac. Res. Clin. Haematol., 17, No. 1, 105–125 (2004).CrossRefGoogle Scholar
  13. 13.
    L. Y. Yukelson, G. Tans, M. Thomassen, et al., Toxicon., 29, Nos. 4–5, 491–502 (1991).PubMedCrossRefGoogle Scholar
  14. 14.
    E. Zavyalova, A. Golovin, R. Reshetnikov, et al., Curr. Med. Chem., 18, No. 22, 3343–3350 (2011).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • E. Yu. Savchik
    • 1
  • T. B. Kalinina
    • 1
  • N. N. Drozd
    • 1
  • V. A. Makarov
    • 1
  • E. G. Zav’yalova
    • 2
    • 3
  • E. N. Lapsheva
    • 2
  • N. N. Mudrik
    • 2
  • A. V. Babij
    • 2
  • G. V. Pavlova
    • 2
    • 5
  • A. V. Golovin
    • 2
    • 4
  • A. M. Kopylov
    • 3
  1. 1.Hematology Research CenterMinistry of Health and Social Development of the Russian FederationMoscowRussia
  2. 2.APTO-PHARMMoscow RegionRussia
  3. 3.Chemical FacultyMoscowRussia
  4. 4.Faculty of Bioengineering and BioinformaticsM. V. Lomonosov Moscow State UniversityMoscowRussia
  5. 5.Institute of Gene BiologyRussian Academy of SciencesMoscowRussia

Personalised recommendations